Joel A. Pearlman
Distinguished in Age-Related Macular Degeneration (ARMD)

Dr. Joel A. Pearlman

Ophthalmology
3 Parkcenter Dr., Suite 100, 
Sacramento, CA 
On Staff At
Accepting New Patients
Distinguished in Age-Related Macular Degeneration (ARMD)
3 Parkcenter Dr., Suite 100, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Pearlman is an Ophthalmologist in Sacramento, California. Dr. Pearlman is rated as a Distinguished provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Retinal Detachment. Dr. Pearlman is currently accepting new patients.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles and participated in 3 clinical trials in the study of Age-Related Macular Degeneration (ARMD).

Graduate Institution
Baylor College Of Medicine
Residency
John Hopkins Hospital
Specialties
Ophthalmology
Licenses
Ophthalmology in CA
Board Certifications
Ophthalmology - Board Certified
Fellowships
John Hopkins Hospital
Hospital Affiliations
Sutter Roseville Medical Center
Oroville Hospital
Enloe Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 14 Less Insurance Carriers -

Locations

3 Parkcenter Dr., Suite 100, Sacramento, CA 95825

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Enrollment Status: Terminated
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: GSK2798745
Study Phase: Phase 1
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy
Enrollment Status: Completed
Publish Date: June 08, 2023
Intervention Type: Drug
Study Drugs: RBM-007 Injectable Solution, Aflibercept, Sham
Study Phase: Phase 2
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
Enrollment Status: Completed
Publish Date: June 08, 2023
Intervention Type: Drug
Study Drug: RBM-007
Study Phase: Phase 2
Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

19 Total Publications

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.
Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.
Journal: Translational vision science & technology
Published: December 19, 2024
Similar Doctors
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Glenn C. Yiu
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Glenn C. Yiu
Ophthalmology

Regents Of The Univ Of Ca

2315 Stockton Blvd, 
Sacramento, CA 
 (2.5 miles away)
916-734-2011
Languages Spoken:
English
See accepted insurances

Glenn Yiu is an Ophthalmologist in Sacramento, California. Dr. Yiu is rated as an Elite provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Cataract Removal.

Elite in Age-Related Macular Degeneration (ARMD)
Dr. Susanna S. Park
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Susanna S. Park
Ophthalmology

Regents Of The Univ Of Ca

4860 Y St, 
Sacramento, CA 
 (2.3 miles away)
Languages Spoken:
English
See accepted insurances

Susanna Park is an Ophthalmologist in Sacramento, California. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). Her top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Vitrectomy, and Bone Marrow Aspiration.

Elite in Age-Related Macular Degeneration (ARMD)
Dr. Ala Moshiri
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Ala Moshiri
Ophthalmology

Regents Of The Univ Of Ca

4860 Y St, 
Sacramento, CA 
 (2.3 miles away)
916-734-8046
Languages Spoken:
English
See accepted insurances

Ala Moshiri is an Ophthalmologist in Sacramento, California. Dr. Moshiri is rated as a Distinguished provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Color Blindness, and Vitrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pearlman's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile